1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related

Interleukin Related

IL

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N2195R
    Nootkatone (Standard)
    Inhibitor
    Nootkatone (Standard) is the analytical standard of Nootkatone. This product is intended for research and analytical applications. Nootkatone, a neuroprotective agent from Vitis vinifera, has antioxidant and anti-inflammatory effects[1]. Nootkatone improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease[2].
    Nootkatone (Standard)
  • HY-121309
    Doxorubicinone
    Inhibitor 98.29%
    Doxorubicinone (Adriamycin aglycone) is the aglycone of the antibiotic Doxorubicin (HY-15142A), i.e., its sugar-free parent nucleus structure. Doxorubicinone does not induce DNA damage or bind to RelA, but still downregulates the expression of pro-inflammatory cytokines (such as TNF, IL-12, etc.) regulated by the NF-κB pathway. Doxorubicinone can be used in sepsis-related research.
    Doxorubicinone
  • HY-N10913
    Chloranthalactone B
    Inhibitor
    Chloranthalactone B, a lindenane-type sesquiterpenoid, is a nature product that could be isolated from Chinese medicinal herb Sarcandra glabra. Chloranthalactone B inhibits the production of inflammatory mediators by inhibiting the AP-1 and p38 MAPK pathways.
    Chloranthalactone B
  • HY-P991699
    Lixarkitug
    Inhibitor 99%
    Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact ADC molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML). The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).
    Lixarkitug
  • HY-138971
    (±)17(18)-EpETE-ethanolamide
    Modulator 98.0%
    (±)17(18)-EpETE-ethanolamide (17,18-EEQ-EA) (compound 17) is an ω-3 endocannabinoid epoxide with cytokine modulation in neuroinflammation studies, antiangiogenic effects in vascular endothelial cells, and vasodilatory effects on coronary arteries.
    (±)17(18)-EpETE-ethanolamide
  • HY-P992034
    APG808
    Inhibitor
    APG808 (PR001) is an anti-human IL-4Rα monoclonal antibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts IL-13 and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis.
    APG808
  • HY-P991522
    Anflekitug
    Inhibitor 99.9%
    SSGJ-613 is a fully human anti-IL-1β monoclonal antibody. SSGJ-613 can be used for the study of gouty arthritis.
    Anflekitug
  • HY-P991150
    Ompekimig
    Inhibitor
    Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis.
    Ompekimig
  • HY-179421
    PROTAC HDAC6 degrader 7
    Inhibitor
    PROTAC HDAC6 degrader 7 is an orally active, highly efficient, and selective PROTAC degrader targeting histone deacetylase 6 (HDAC6) (IC50 = 118 nM). PROTAC HDAC6 degrader 7 can eliminate both the catalytic and zinc-finger ubiquitin-binding domain. PROTAC HDAC6 degrader 7 inhibits NLRP3 inflammasome assembly and activation, as well as blocks NF-κB signaling, thereby reducing the transcription and release of key inflammatory factors. PROTAC HDAC6 degrader 7 can reduce the mRNA levels of NLRP3, pro-IL-1β, TNF-α, and IL-6. PROTAC HDAC6 degrader 7 can be used for the study of inflammatory bowel disease (IBD).
    PROTAC HDAC6 degrader 7
  • HY-178037
    TLR9 antagonist 1
    Inhibitor
    TLR9 antagonist 1 is a selective hTLR9 antagonist with an IC50 of 0.1 nM against hTLR9. TLR9 antagonist 1 exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 can be used in the research of systemic lupus erythematosus.
    TLR9 antagonist 1
  • HY-106087
    IX 207-887
    Inhibitor 98.96%
    IX 207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1).
    IX 207-887
  • HY-P4890A
    Relaxin H3 (human) TFA
    Inhibitor
    Relaxin H3 (human) TFA is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) TFA acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) TFA inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) TFA activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) TFA can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
    Relaxin H3 (human) TFA
  • HY-148693
    OSM-SMI-8
    Antagonist
    OSM-SMI-8 (NSC642624) is a potent OSM (oncostatin M) antagonist. OSM-SMI-8 has the potential for the research of cancer.
    OSM-SMI-8
  • HY-113224R
    Desmosterol (Standard)
    Inhibitor
    Desmosterol (Standard) is the analytical standard of Desmosterol. This product is intended for research and analytical applications. Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism [1]. Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases [1][2][3].
    Desmosterol (Standard)
  • HY-P992109
    Eftezirleukin alfa
    Eftezirleukin alfa is a human immunoglobulin G4 (IgG4) Fc fragment. Eftezirleukin alfa is associated with IL-2.
    Eftezirleukin alfa
  • HY-141535A
    IL-17 modulator 1 disodium
    Modulator 98.38%
    IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis.
    IL-17 modulator 1 disodium
  • HY-P990058
    Varokibart
    Inhibitor
    Varokibart (TEV-53275) is a human IgG4λ antibody targeting IL5.
    Varokibart
  • HY-P991729
    Zumilokibart
    Inhibitor
    Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zumilokibart can be used for the research of atopic dermatitis (AD).
    Zumilokibart
  • HY-RS06775
    Il6 Mouse Pre-designed siRNA Set A
    Inhibitor

    Il6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il6 Mouse Pre-designed siRNA Set A
  • HY-109569
    Vitamin K2
    Inhibitor ≥98.0%
    Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma.
    Vitamin K2
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.